Dyne Therapeutics (NASDAQ:DYN) Director Acquires $43,700.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner bought 2,500 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average price of $17.48 per share, for a total transaction of $43,700.00. Following the completion of the transaction, the director directly owned 22,500 shares of the company’s stock, valued at $393,300. This represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Dyne Therapeutics Stock Performance

NASDAQ DYN traded down $1.37 on Friday, hitting $17.04. 1,882,492 shares of the company traded hands, compared to its average volume of 1,967,476. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -5.29 and a beta of 1.09. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average price is $18.32 and its 200-day moving average price is $18.29. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the previous year, the company earned ($1.05) EPS. Equities analysts expect that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DYN. Chardan Capital reiterated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Sanford C. Bernstein lifted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Hedge Funds Weigh In On Dyne Therapeutics

Large investors have recently made changes to their positions in the business. Hilton Head Capital Partners LLC purchased a new position in shares of Dyne Therapeutics in the first quarter valued at about $26,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics in the fourth quarter valued at about $51,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Dyne Therapeutics in the fourth quarter valued at about $84,000. Steward Partners Investment Advisory LLC lifted its position in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after buying an additional 1,109 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.